التفاصيل البيبلوغرافية
| العنوان: |
[Exclusivity of data in drug registration files and Israel's international status with regard to intellectual property rights protection]. |
| المؤلفون: |
Lipschitz Y; The Israeli Center for Technology Assessment in Health Care, The Gertner Institute for Epidemiology and Health Policy Research, Tel Hashomer. YOEL.LIPSCHITZ@MOH.HEALTH.GOV.IL, Tamir O, Shemer J |
| المصدر: |
Harefuah [Harefuah] 2004 Dec; Vol. 143 (12), pp. 845-8, 912. |
| نوع المنشور: |
English Abstract; Journal Article |
| اللغة: |
Hebrew |
| بيانات الدورية: |
Publisher: Israel Medical Association Country of Publication: Israel NLM ID: 0034351 Publication Model: Print Cited Medium: Print ISSN: 0017-7768 (Print) Linking ISSN: 00177768 NLM ISO Abbreviation: Harefuah Subsets: MEDLINE |
| أسماء مطبوعة: |
Original Publication: Tel Aviv : Israel Medical Association |
| مواضيع طبية MeSH: |
Intellectual Property* , Registries*, Copyright/*legislation & jurisprudence , Drug Industry/*legislation & jurisprudence , Drug Therapy/*statistics & numerical data, Israel |
| مستخلص: |
Protecting intellectual property rights encourages creativity and innovation, which are key measures for research and development of new drugs and also promotes the introduction of drugs to new markets. Over the past years, many countries have enacted laws implementing the protection of data in drug registration files. Until recently, Israel has not provided any form of data protection. Current moves focus on new legislation granting exclusivity in the marketing of innovative drugs. Although controversial, this legislation aims to secure balance in Israel between the innovative pharmaceutical companies and the public's interest in competitive generic drugs. |
| تواريخ الأحداث: |
Date Created: 20050126 Date Completed: 20050222 Latest Revision: 20061115 |
| رمز التحديث: |
20231215 |
| PMID: |
15666700 |
| قاعدة البيانات: |
MEDLINE |
